Welcome
Groundbreaking Anti-Cancer Regiment For Your Canine
We're dedicated to your pups health! Click below to learn why WayPath is different.
Site Content
News and Insights
News and Insights
News and Insights
WayPath Pharma in the News
Press Release
Announcements
News and Insights
News and Insights
- September 2022 marks the start of our STTR Phase 1 grant from the NIH
- August 2024 Submitted Phase II
What We Do
Early Days
Early work resulted in formulating an orally administered compound, pre-clinical testing, and a pilot study with promising results. The pilot study in a canine diagnosed with Hemangiosarcoma (HSA) showed a healthy life extension of +26 months, treated by a daily oral dose of the compound, demonstrably MORE than the 2-weeks life expectancy post diagnosis without treatment.
Commitment to Innovation
The WayPath team brings together a group of experienced specialists in cancer research and chemistry. Dr Krzysztof Reiss, co-founded WayPath after he successfully treated his canine companion, which was diagnosed with HSA.
Dr. Reiss has over 165 publications related to cell signaling, energy metabolism, DNA repair, oncogenic viruses and brain tumor experimental models
Help in our commitment
In need of a partner to execute next steps to help canines
- Fund animal trials and acquire necessary laboratory equipment
- Complete toxicology study in canines
- Conduct large scale canine clinical trials
- Complete the FDA’s New Animal Drug Application process
Subscribe
Copyright © 2024 WayPath - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.